miR-200a-3p promotes b-Amyloid-induced neuronal apoptosis through down-regulation of SIRT1 in Alzheimer's disease

J Biosci. 2017 Sep;42(3):397-404. doi: 10.1007/s12038-017-9698-1.

Abstract

The aberrantly expressed microRNAs (miRNAs) including miR-200a-3p have been reported in the brains of Alzheimer's disease (AD) patients in recent researches. Nevertheless, the role of miR-200a-3p in AD has not been characterized. The purpose of this study was to examine whether miR-200a-3p regulated β-Ameyloid (A β)-induced neuronal apoptosis by targeting SIRT1, a known anti-apoptotic protein. An increased level of miR-200a-3p and a decreased level of SIRT1 in the hippocampus of APPswe/PS delta E9 mice (a model for AD) were observed. To construct an in vitro cell model of AD, PC12 cells were cultured in presence of A β 25-35. The results of flow cytometry analysis showed that the apoptosis rate and cleaved-caspase-3 expression in PC12 cells exposed to A β 25-35 were remarkably increased, but the apoptosis rate and cleaved-caspase-3 activity were decreased when cells were transfected with anti-miR-200a-3p. On the other hand, MTT assay showed that the cell survival rate was increased in the A β 25-35 + anti-miR-200a-3p group compared with the A β 25-35 + anti-miR-NC group. Dual-luciferase reporter gene assay validated the predicted miR-200a-3p binding sites in the 3'- UTR of SIRT1 mRNA. In addition, downregulation of SIRT1 promoted A β25-35-induced neuronal apoptosis and cleavedcaspase- 3 level in PC12 cells, whereas anti-miR-200a-3p reversed these effects. Knockdown of SIRT1 decreased the inhibitory effect of A β 25-35 on cell viability, while anti-miR-200a-3p attenuated this effect. Overall, the results suggest that suppression of miR-200a-3p attenuates A β 25-35-induced apoptosis in PC12 cells by targeting SIRT1. Thus, miR-200a-3p may be a potential therapeutic target for treatment of AD.

MeSH terms

  • Alzheimer Disease / genetics*
  • Alzheimer Disease / metabolism
  • Alzheimer Disease / pathology
  • Amyloid beta-Peptides / pharmacology*
  • Amyloid beta-Protein Precursor / genetics
  • Amyloid beta-Protein Precursor / metabolism
  • Animals
  • Antagomirs / genetics
  • Antagomirs / metabolism
  • Apoptosis / drug effects
  • Apoptosis / genetics
  • Base Sequence
  • Binding Sites
  • Caspase 3 / genetics*
  • Caspase 3 / metabolism
  • Cell Differentiation
  • Disease Models, Animal
  • Gene Expression Regulation
  • Hippocampus / metabolism
  • Hippocampus / pathology
  • Humans
  • Mice
  • Mice, Transgenic
  • MicroRNAs / antagonists & inhibitors
  • MicroRNAs / genetics*
  • MicroRNAs / metabolism
  • Neurons / drug effects*
  • Neurons / metabolism
  • Neurons / pathology
  • PC12 Cells
  • Peptide Fragments / pharmacology*
  • Presenilin-1 / genetics
  • Presenilin-1 / metabolism
  • RNA, Small Interfering / genetics
  • RNA, Small Interfering / metabolism
  • Rats
  • Signal Transduction
  • Sirtuin 1 / antagonists & inhibitors
  • Sirtuin 1 / genetics*
  • Sirtuin 1 / metabolism

Substances

  • Amyloid beta-Peptides
  • Amyloid beta-Protein Precursor
  • Antagomirs
  • MicroRNAs
  • Mirn200 microRNA, mouse
  • Peptide Fragments
  • Presenilin-1
  • RNA, Small Interfering
  • amyloid beta-protein (25-35)
  • presenilin 1, mouse
  • Casp3 protein, rat
  • Caspase 3
  • Sirt1 protein, mouse
  • Sirtuin 1